Lawmakers in New York this month approved wide-ranging legislation designed to require pricing transparency from PBMs and to eliminate key PBM practices, including so-called “spread pricing,” mid-year formulary shuffling and drug substitutions. But the bill could potentially limit plans’ ability to respond to pricing moves by manufacturers, one consultant says.
To access this post, you must purchase a subscription plan. Click Here to purchase.

Already a member? Click Here to login.